Skip to main content

Table 1 Targeted bis-seq data for methylation in 20 candidate genes (29 amplicons) in 24 paired HCC tumor and adjacent non-tumor tissues

From: Integrative epigenomic and genomic filtering for methylation markers in hepatocellular carcinomas

Gene symbol

Amplicons name

No. of covered CpG sites

Non-tumor

Tumor

Difference

Adjusted P value *

Mean, SD

Mean, SD

CDKL2

CDKL2.a

11

6.49 (8.35)

33.52 (18.80)

27.03

2.50E-04

CDKL2

CDKL2.b

15

7.59 (11.57)

41.29 (21.98)

33.70

1.94E-04

CDKL2

CDKL2.c

27

13.20 (13.50)

37.15 (20.68)

23.95

2.83E-02

CLCN1

CLCN1

28

16.31 (10.83)

47.84 (21.93)

31.53

3.01E-04

DUOX1

DUOX1

36

16.93 (16.93)

36.98 (24.43)

20.05

2.77E-01

GRASP

GRASP.a

24

12.66 (8.70)

42.45 (23.56)

29.79

3.92E-04

ILDR2

ILDR2.a

23

7.66 (4.22)

43.18 (27.32)

35.52

4.21E-05

MAST1

MAST1.a

16

16.40 (20.56)

59.15 (33.23)

42.75

4.99E-04

MAST1

MAST1.b

2

10.42 (10.98)

34.74 (21.02)

24.32

4.33E-03

MAST1

MAST1.c

19

15.25 (8.44)

38.92 (14.03)

23.67

5.15E-05

NKX6-2

NKX6-2.b

24

26.17 (9.56)

54.97 (17.70)

28.80

4.25E-05

OTX1

OTX1.a

8

22.53 (9.14)

52.15 (24.09)

29.62

2.63E-03

OTX1

OTX1.b

28

17.68 (12.10)

49.60 (17.44)

31.92

1.85E-04

SERHL

SERHL.a

16

11.94 (4.38)

35.71 (13.19)

23.77

3.82E-07

SERHL

SERHL.b

11

4.86 (2.26)

17.15 (12.24)

12.29

1.08E-03

SPAG6

SPAG6.b

53

16.07 (5.05)

34.12 (15.67)

18.04

1.59E-03

SPDYA

SPDYA.b

11

46.93 (17.40)

73.91 (18.14)

26.98

1.29E-02

TRIL

TRIL.a

16

18.13 (6.02)

53.25 (20.58)

35.12

1.01E-05

TRIL

TRIL.b

22

13.88 (8.85)

36.95 (17.75)

23.07

2.22E-03

TRIL

TRIL.c

17

9.73 (6.70)

41.44 (17.52)

31.71

6.62E-06

TRIL

TRIL.e

44

12.10 (10.22)

38.52 (19.07)

26.42

1.55E-03

TSPYL5

TSPYL5

57

13.83 (12.12)

41.21 (18.79)

27.38

8.09E-04

USP44

USP44.c

9

61.31 (10.17)

73.45 (10.01)

12.14

6.81E-03

ZNF397OS

ZNF397OS.a

32

13.76 (11.59)

38.94 (18.21)

25.18

3.10E-04

FAM66B

FAM66B

13

91.18 (3.59)

71.89 (17.30)

−19.29

9.49E-04

KCNQ2

KCNQ2

44

74.06 (14.65)

45.21 (22.68)

−28.85

3.99E-03

PROKR2

PROKR2

14

83.57 (14.68)

65.11 (12.97)

−18.46

1.11E-02

PTPRN2

PTPRN2

8

74.68 (11.71)

53.60 (17.39)

−21.08

6.50E-03

REXO1L2P

REXO1L2P

12

84.14 (14.58)

53.98 (22.99)

−30.16

1.75E-03

  1. * All adjusted p values are less than 0.05 with Bonferroni correction for multiple testing except DUOX1